SG11201406903SA - Cell culture compositions and methods for polypeptide production - Google Patents

Cell culture compositions and methods for polypeptide production

Info

Publication number
SG11201406903SA
SG11201406903SA SG11201406903SA SG11201406903SA SG11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA
Authority
SG
Singapore
Prior art keywords
south san
san francisco
dna way
international
cell culture
Prior art date
Application number
SG11201406903SA
Other languages
English (en)
Inventor
Steven J Meier
Melissa S Mun
Natarajan Vijayasankaran
Sharat Varma
Yi Yang
Boyan Zhang
Silvana R Arevalo
Martin Gawlitzek
Veronica Carvalhal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201406903S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201406903SA publication Critical patent/SG11201406903SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/005Protein-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/24Iron; Fe chelators; Transferrin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/38Vitamins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201406903SA 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production SG11201406903SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261637778P 2012-04-24 2012-04-24
US201261637780P 2012-04-24 2012-04-24
US13/841,864 US20130281355A1 (en) 2012-04-24 2013-03-15 Cell culture compositions and methods for polypeptide production
PCT/US2013/037992 WO2013163294A1 (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production

Publications (1)

Publication Number Publication Date
SG11201406903SA true SG11201406903SA (en) 2014-12-30

Family

ID=49380652

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810830UA SG10201810830UA (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production
SG11201406903SA SG11201406903SA (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201810830UA SG10201810830UA (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production

Country Status (22)

Country Link
US (2) US20130281355A1 (es)
EP (2) EP3533864A1 (es)
JP (4) JP6367792B2 (es)
KR (2) KR102115052B1 (es)
CN (2) CN111440758A (es)
AR (1) AR090822A1 (es)
AU (2) AU2013251647B2 (es)
BR (1) BR112014026308A8 (es)
CA (1) CA2871006C (es)
ES (1) ES2716301T3 (es)
HK (1) HK1208496A1 (es)
HR (1) HRP20190484T1 (es)
IL (1) IL235235A0 (es)
MX (2) MX363493B (es)
MY (1) MY181513A (es)
NZ (1) NZ701791A (es)
PL (1) PL2841561T3 (es)
RU (2) RU2018146497A (es)
SG (2) SG10201810830UA (es)
SI (1) SI2841561T1 (es)
WO (1) WO2013163294A1 (es)
ZA (2) ZA201408092B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
KR102202476B1 (ko) * 2013-03-15 2021-01-12 제넨테크, 인크. 세포 배양 배지 및 항체 생산 방법
EP3712252A1 (en) 2013-03-15 2020-09-23 F. Hoffmann-La Roche AG Cell culture compositions with antioxidants and methods for polypeptide production
US9598667B2 (en) * 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3639171A4 (en) * 2017-06-16 2021-07-28 Cytiva Sweden AB PROCESS FOR PREDICTING THE RESULT AND MODELING A PROCESS IN A BIOREACTOR
EP3492582A1 (en) 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods
CN108823267B (zh) * 2018-06-25 2020-05-08 深圳市菲鹏生物制药股份有限公司 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法
EP4051790A4 (en) * 2019-10-31 2023-11-01 William Marsh Rice University GENETICALLY ENGINEERED CELLS FOR CONTROLLED PRODUCTION
BR112021025438A2 (pt) 2019-12-06 2022-06-21 Regeneron Pharma Composições de proteínas anti-vegf e métodos para produzir as mesmas
MX2022008339A (es) 2020-01-31 2022-08-04 Chugai Pharmaceutical Co Ltd Metodo para producir una composicion que contiene un polipeptido con coloracion suprimida.
JP7404930B2 (ja) 2020-02-26 2023-12-26 富士フイルムビジネスイノベーション株式会社 発光装置、光学装置及び計測装置
JP7404929B2 (ja) 2020-02-26 2023-12-26 富士フイルムビジネスイノベーション株式会社 発光装置、光学装置及び計測装置
GB202012991D0 (en) 2020-08-20 2020-10-07 Ucb Biopharma Sprl Cell culture processes
US20220251502A1 (en) * 2020-12-22 2022-08-11 Novartis Ag Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
KR20240050373A (ko) 2021-09-02 2024-04-18 베링거 인겔하임 인터내셔날 게엠베하 미래의 색값 또는 대응하는 특성을 결정하는 방법 및 이를 위한 장치
KR20230051921A (ko) * 2021-10-12 2023-04-19 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5863385A (ja) 1981-10-02 1983-04-15 ハナ・バイオロジツクス・インコ−ポレ−テツド 免疫系由来の細胞用培地
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH03180176A (ja) * 1989-11-16 1991-08-06 W R Grace & Co 細胞培養のための基礎栄養培地
CA2068204C (en) 1989-11-22 2002-02-12 Arthur Levinson Latency associated peptides and uses therefor
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
JPH07102147B2 (ja) * 1992-03-16 1995-11-08 株式会社ミドリ十字 ヒト血清アルブミンの着色抑制方法
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5512477A (en) 1994-04-21 1996-04-30 Genzyme Corporation Serum-free medium supplement
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69623109T2 (de) * 1996-04-19 2002-12-12 Nestle Sa Menschliche immortalisierte Colon-Epithelialzellen
US6103529A (en) 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20060286668A1 (en) 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
US6900056B2 (en) * 2001-02-15 2005-05-31 Centocor, Inc. Chemically defined medium for cultured mammalian cells
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20070134759A1 (en) * 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1812557A4 (en) 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
CN100569940C (zh) * 2006-08-16 2009-12-16 华东理工大学 人胚胎肾(hek)293细胞无血清培养基
WO2008033517A2 (en) * 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
AU2007331712A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
WO2008084857A1 (ja) * 2007-01-12 2008-07-17 Nippon Sheet Glass Company, Limited 三次元細胞培養担体およびそれを用いた細胞培養方法
KR101022032B1 (ko) * 2007-07-20 2011-03-16 동국대학교 산학협력단 중간엽 줄기세포를 이용하여 모유두 조직을 제조하는 방법
WO2009029795A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
PL2310523T3 (pl) * 2008-04-17 2015-10-30 Wyeth Llc Sposoby zwiększonego wytwarzania białek morfogenetycznych kości
KR20110060911A (ko) * 2008-09-26 2011-06-08 쉐링 코포레이션 고 역가 항체 생산
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
KR101828623B1 (ko) 2010-04-26 2018-02-12 노파르티스 아게 개선된 세포 배양 배지

Also Published As

Publication number Publication date
CA2871006A1 (en) 2013-10-31
US20240093143A1 (en) 2024-03-21
HRP20190484T1 (hr) 2019-05-17
JP7323272B2 (ja) 2023-08-08
ZA201408092B (en) 2019-03-27
JP2018183154A (ja) 2018-11-22
AU2013251647A1 (en) 2014-12-18
US20130281355A1 (en) 2013-10-24
AR090822A1 (es) 2014-12-10
EP2841561B1 (en) 2019-01-16
EP3533864A1 (en) 2019-09-04
MX2014012838A (es) 2015-10-22
BR112014026308A8 (pt) 2021-06-01
SG10201810830UA (en) 2018-12-28
NZ701791A (en) 2017-03-31
KR20200057795A (ko) 2020-05-26
RU2014147018A (ru) 2016-06-10
AU2019202259B2 (en) 2021-11-11
CA2871006C (en) 2021-05-25
MY181513A (en) 2020-12-24
KR20150003351A (ko) 2015-01-08
KR102115052B1 (ko) 2020-05-25
JP2021104023A (ja) 2021-07-26
CN111440758A (zh) 2020-07-24
HK1208496A1 (en) 2016-03-04
JP2015515281A (ja) 2015-05-28
SI2841561T1 (sl) 2019-04-30
MX363493B (es) 2019-03-26
ES2716301T3 (es) 2019-06-11
WO2013163294A1 (en) 2013-10-31
KR102339106B1 (ko) 2021-12-15
AU2013251647B2 (en) 2019-04-04
MX2019003427A (es) 2020-11-12
JP6367792B2 (ja) 2018-08-01
BR112014026308A2 (pt) 2017-06-27
ZA201707452B (en) 2021-03-31
CN104428409A (zh) 2015-03-18
JP2023156371A (ja) 2023-10-24
PL2841561T3 (pl) 2019-05-31
RU2018146497A (ru) 2019-02-04
AU2019202259A1 (en) 2019-04-18
RU2678142C2 (ru) 2019-01-23
IL235235A0 (en) 2014-12-31
EP2841561A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201407768QA (en) Generating pluripotent cells de novo
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201407427WA (en) Extreme pcr
SG11201408261UA (en) Syringe
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions